Abbott Laboratories Management Discusses Q2 2012 Results – Earnings Call …Seeking AlphaDaclizumab is a next-generation biologic for MS, currently in late-stage development with a partner company. Results from the Phase III study are expected in 2014….
el periodicBelenguer afirma que las nuevas terapias biológicas son más eficaces en el …el periodic… dos de las nuevas terapias biológicas: los agentes orales (Fingolimod, Dimetil Fumarato, Laquinimod y Teriflunomida); y los anticuerpos monoclona…
Abbott Reports Strong Second Quarter ResultsEquities.comAbbott is partnering on the development of a novel, next-generation antibody, daclizumab, which is currently in Phase 3 clinical trials for MS. Additionally, Abbott recently announced positive res…
RTT NewsAbbott Beats on EPS, Affirms View – Analyst BlogNASDAQAbbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working…
Abbott Beats on EPS, Affirms ViewZacks.comAbbott Labs, along with partner Biogen (BIIB – Analyst Report), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on l…
Abbott Reports Strong Second Quarter ResultsMarketWatch (press release)Abbott is partnering on the development of a novel, next-generation antibody, daclizumab, which is currently in Phase 3 clinical trials for MS. Additionally, Abbott recently announc…
각종 신계열 신약 출시 기대디지틀보사… C형 간염에 '아수나프레비어'(asunaprevir), 'BI 201335', '시메프레비어'(simeprevir), 다발성 경화증에 면역조절제인 '라퀴니모드'(laqu…
Despite likely new MS drugs, US neurologists continue to see significant near …The Pharma LetterIn fact, interest in BG-12, along with Biogen Idec's PEG-Avonex, Abbott/Biogen Idec's daclizumab and Roche/Genentech's ocrelizumab, has increa…
BioTrends Research GroupPosted on:28 Jun 12PharmiWeb.com (press release)In fact, interest in BG-12, along with Biogen Idec‚Äôs PEG-Avonex, Abbott / Biogen Idec‚Äôs daclizumab and Roche / Genentech‚Äôs ocrelizumab, has increased significantl…
Steroid-Free Regimen Post-Pediatric Renal Transplant SafeDoctors LoungeParticipants were randomly allocated to steroid-free (SF) or steroid-based (SB) immunosuppression, together with tacrolimus, mycophenolate, and standard or extended-dose daclizumab …